reporter: r4 李育庭 supervisor: 鄧豪偉醫師
DESCRIPTION
Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome Ann Surg Oncol (2012) 19:2797–2804 Aleksey V. George A. Poultsides , Fei Bao , Elliot L. Servais et al. Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師. Introduction - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/1.jpg)
Pathologic Response to Preoperative Chemotherapy in Colorectal
Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome
Ann Surg Oncol (2012) 19:2797–2804 Aleksey V. George A. Poultsides, Fei Bao, Elliot L. Servais et al.
Reporter: R4 李育庭Supervisor: 鄧豪偉醫師
![Page 2: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/2.jpg)
Introduction Patient and Method Result Discussion Conclusion
![Page 3: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/3.jpg)
Introduction
3
![Page 4: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/4.jpg)
Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients.
Nordlinger B, Sorbye H, Glimelius B, et al. Lancet. Mar 22 2008;371(9617):1007-1016.
![Page 5: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/5.jpg)
Nordlinger B, Sorbye H, Glimelius B, et al. Lancet. Mar 22 2008;371(9617):1007-1016.
![Page 6: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/6.jpg)
Systemic chemotherapy has been shown to convert initially unresectable tumors to resectable.
![Page 7: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/7.jpg)
Adam R, Delvart V, Pascal G, et al. Annals of surgery 2004;240:644-57.
![Page 8: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/8.jpg)
Pathologic response predicts survival after preoperative chemotherapy and resection of CLM (Colorectal liver metastasis).
![Page 9: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/9.jpg)
9
Blazer DG, 3rd, Kishi Y, Maru DM, et al. J Clin Oncol 26:5344-51, 2008
Residual tumor
complete 0%
major 1-49%
minor >50%
![Page 10: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/10.jpg)
10
Adam R, Wicherts DA, de Haas RJ, et al. J Clin Oncol 26:1635-41, 2008
![Page 11: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/11.jpg)
11
Rubbia-Brandt L, Giostra E, Brezault C, et al. Ann Oncol 18:299-304, 2007
![Page 12: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/12.jpg)
The pathologic response to neoadjuvant therapy in primary colorectal cancer is not homogeneous.FibrosisNecrosisAcellular mucin
Rubbia-Brandt L, Giostra E, Brezault C, et al. Ann Oncol 18:299-304, 2007
![Page 13: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/13.jpg)
Purpose To evaluate the prevalence of the three
components of pathologic response (necrosis, fibrosis, acellular mucin) after resection of CLM, with and without preoperative chemotherapy.
To investigate the association with outcome as well as preoperative factors
![Page 14: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/14.jpg)
Patient and Methods
14
![Page 15: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/15.jpg)
A single institution Retrospective review
![Page 16: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/16.jpg)
Patient Preoperative chemotherapy :
Systemic chemotherapy within 6 months before hepatectomy
Hepatic artery infusion Non Preoperative chemotherapy
Chemotherapy-naive patients chemotherapy-free interval of more than 6
months before hepatectomy
Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 17: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/17.jpg)
17Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 18: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/18.jpg)
A median of 3 slides (range, 1–17) were examined for each tumor, typically one section per centimeter of tumor diameter.
All tumors that grossly appeared to show complete or near complete response.
![Page 19: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/19.jpg)
Result
19
![Page 20: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/20.jpg)
20Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 21: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/21.jpg)
21
Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 22: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/22.jpg)
Of 21 complete pathologic responders, all but one had received preoperative chemotherapy.
5-year survival probability: 94%N Character
7 >90% Necrosis
6 >90% Fibrosis
3 >90% Mucin
5 Mixed pattern
Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 23: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/23.jpg)
Preoperative chemotherapy
23
Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 24: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/24.jpg)
Preoperative chemotherapy
24
Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 25: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/25.jpg)
25
![Page 26: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/26.jpg)
Non Preoperative chemotherapy Only 9 (8 %) and 3 (3 %) of the 117
nonchemotherapy patients had ≥75 % nonviable tumor and fibrosis ≥ 40 %.
Lack of association with disease-specific survival
![Page 27: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/27.jpg)
27
![Page 28: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/28.jpg)
Discussion
28
![Page 29: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/29.jpg)
Fibrosis is the predominant chemotherapy-induced pathologic change in CLM.
Necrosis in CLM is more related to spontaneous phenomena.
The beneficial effects of chemotherapy appear to be mainly related to the replacement of tumor by fibrosis
29
![Page 30: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/30.jpg)
The study is the first to provide a detailed quantitative analysis of the three components of overall pathologic response (fibrosis, necrosis, acellular mucin)
Fibrosis as the main chemotherapy-induced pathologic change independently associated with survival after resection of CLM.
30
![Page 31: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/31.jpg)
8 % were found to have a complete absence of viable tumor cells on pathologic review
In the study, patients with complete pathologic response had a 94 % 5-year disease-specific survival probability.
31
![Page 32: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/32.jpg)
It is important to identify patient or tumor characteristics that preoperatively predict higher levels of pathologic response.
32
Tumor size (after treatment) < 3 cm
High CEA >200ng/ml
Hepatic artery infusion
Bevacizumab + Oxaliplatin based chemotherapy
![Page 33: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/33.jpg)
Bevacizumab + Oxaliplatin based chemotherapy
33
Ribero D, Wang H, Donadon M, et al. Cancer 110:2761-7, 2007
![Page 34: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/34.jpg)
Bevacizumab + Oxaliplatin based chemotherapy
34
Blazer DG, 3rd, Kishi Y, Maru DM, et al. J Clin Oncol 26:5344-51, 2008
![Page 35: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/35.jpg)
Bevacizumab + Oxaliplatin based chemotherapy
35
Klinger M, Tamandl D, Eipeldauer S, et al. Ann Surg Oncol 17:2059-65, 2010
![Page 36: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/36.jpg)
Duration of chemotherapy Longer duration of preoperative
chemotherapy was not associated with pathological response
36
Poultsides GA, Bao F, Servais EL, et al. Ann Surg Oncol 19:2797-804, 2012
![Page 37: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/37.jpg)
Duration of chemotherapy
37
Kishi Y, Zorzi D, Contreras CM, et al.Ann Surg Oncol 17:2870-6, 2010
![Page 38: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/38.jpg)
Conclusion
38
![Page 39: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/39.jpg)
Approximately 8 % of patients with CLM receiving modern combination chemotherapy can achieve complete pathologic response.
Favorable overall pathologic response is associated with improved long-term survival.
The pathologic finding of necrosis in CLM is a nonspecific finding.
39
![Page 40: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/40.jpg)
HAI chemotherapy and bevacizumab may be associated with higher rates of overall pathologic response and fibrosis.
40
![Page 41: Reporter: R4 李育庭 Supervisor: 鄧豪偉醫師](https://reader036.vdocuments.site/reader036/viewer/2022081417/568167d3550346895ddd2584/html5/thumbnails/41.jpg)